Advertisement
U.S. markets closed
  • S&P 500

    5,254.35
    +5.86 (+0.11%)
     
  • Dow 30

    39,807.37
    +47.29 (+0.12%)
     
  • Nasdaq

    16,379.46
    -20.06 (-0.12%)
     
  • Russell 2000

    2,124.55
    +10.20 (+0.48%)
     
  • Crude Oil

    83.11
    +1.76 (+2.16%)
     
  • Gold

    2,254.80
    +42.10 (+1.90%)
     
  • Silver

    25.10
    +0.35 (+1.41%)
     
  • EUR/USD

    1.0793
    -0.0036 (-0.33%)
     
  • 10-Yr Bond

    4.2060
    +0.0100 (+0.24%)
     
  • GBP/USD

    1.2624
    -0.0014 (-0.11%)
     
  • USD/JPY

    151.3640
    +0.1180 (+0.08%)
     
  • Bitcoin USD

    70,829.50
    +1,707.77 (+2.47%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • FTSE 100

    7,952.62
    +20.64 (+0.26%)
     
  • Nikkei 225

    40,168.07
    -594.66 (-1.46%)
     

Scotts Miracle Gro Q4 Earnings Preview

On Wednesday, Nov. 7, Scotts Miracle Gro (NYSE: SMG) will release its latest earnings report. Benzinga's outlook for Scotts Miracle Gro is included in the following report.

Earnings and Revenue

Wall Street analysts see Scotts Miracle Gro reporting a loss of 67 cents per share on revenue of $441.1 million.

In the same quarter last year, Scotts Miracle Gro reported a loss per share of 26 cents on revenue of $376.7 million. Sales would be up 17.1 percent from the year-ago period. Here's how the company's EPS has stacked up against analyst estimates in the past:

View more earnings on SMG

Quarter

Q3 2018

Q2 2018

Q1 2018

Q4 2017

EPS Estimate

2.58

3.44

-0.93

-0.34

EPS Actual

2.67

2.88

-1.08

-0.26

Stock Performance

Over the past 52-week period, shares of Scotts Miracle Gro have declined 29.56 percent. Given that these returns are generally negative, long-term shareholders are probably a little upset going into this earnings release. Long-term shareholders are already enjoying 12-month gains prior to the announcement.

Analysts have adjusted their estimates lower for EPS and revenues over the past 90 days. Analysts generally rate Scotts Miracle Gro stock as Sell. The strength of this rating has maintained conviction over the past three months.

See more from Benzinga

© 2018 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Advertisement